Radiosurgery Plus Bevacizumab in Glioblastoma

Inclusion * Histologically proven diagnosis of glioblastoma or gliosarcoma (WHO grade IV) at primary or subsequent resection * Radiographic evidence of tumor progression as defined by a contrast enhanced MRI at least 3 months after the completion of radiation therapy * Unifocal enhancing disease; the enhancing focus must be =\< 3 cm in maximum diameter * History/physical examination within 14 days prior to registration * The patient must have recovered from the effects of prior therapy before study entry * The patient must not have received chemotherapy within the following time frames: Non-cytotoxic agents: 2 weeks, cytotoxic agents: 3 weeks, nitrosoureas: 6 weeks * Must be able to undergo MRI imaging * Documentation of steroid doses within 14 days prior to registration * Karnofsky performance status \> 60 * Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 * Platelets \>= 100,000 cells/mm\^3 * Hemoglobin \>= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb \>= 10.0 g/dl is acceptable) * BUN =\< 30 mg/dl within 14 days prior to study entry * Creatinine =\< 1.7 mg/dl within 14 days prior to study entry * Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio; for UPC ratio \> 0.5, 24-hour urine protein should be obtained and the level should be \< 1000 mg * Bilirubin =\< 2.0 mg/dl within 14 days prior to study entry * ALT/AST =\< 3 x normal range within 14 days prior to study entry * Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study entry * Prothrombin time/international normalized ratio (PT INR) \< 1.4 for patients not on warfarin confirmed by testing within 14 days prior to study entry * Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria: No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices); in-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin * Patients must provide study specific informed consent prior to study entry * Women of childbearing potential and male participants must practice adequate contraception * For females of child-bearing potential, negative serum pregnancy test within 14 days prior to entry Exclusion * Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for \>= 3 years (for example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible) * More than one focus of enhancement * Involvement of the brainstem (defined as the midbrain or lower) * Prior use of chemotherapy wafers or any other intratumoral or intracavitary treatment are not permitted; prior radiosurgery is not permitted * Prior treatment with intravenous bevacizumab * Unstable angina and/or congestive heart failure within the last 6 months * Transmural myocardial infarction within the last 6 months * Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of \>= 2 mm using the analysis of an EKG performed within 14 days of entry * New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration * History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months * Serious and inadequately controlled cardiac arrhythmia * Uncontrolled hypertension * Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for tumor resection * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of entry * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of entry * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol * Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol * Active connective tissue disorders, such as lupus or scleroderma that in the opinion of the treating physician may put the patient at high risk for radiation toxicity * Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug * Patients treated on any other therapeutic clinical trials within 30 days prior to study entry or during participation in the study * Growth factors are not permitted to induce elevations in neutrophil count for the purposes of: 1) administration of temozolomide on the scheduled dosing interval; 2) allowing treatment with temozolomide at a higher dose; or 3) avoiding interruption of the treatment during concomitant radiotherapy * No other investigational drugs will be allowed during this study * Surgical procedures for tumor debulking, other types of chemotherapy, and immunotherapy or biologic therapy must not be used * Additional stereotactic boost radiotherapy is not allowed